Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Jose M Pacheco

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone720/848-5463

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Front Oncol. 2020; 10:510. PMID: 32351892.
      View in: PubMed
    2. Pacheco JM. KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer. Transl Lung Cancer Res. 2020 Feb; 9(1):148-153. PMID: 32206562.
      View in: PubMed
    3. Pacheco JM. Approach to stage IV non-small-cell lung cancer: how to select among first-line therapy options? Curr Opin Pulm Med. 2019 Dec 30. PMID: 31895119.
      View in: PubMed
    4. Pacheco JM, Moghanaki D. Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain. Transl Lung Cancer Res. 2019 Dec; 8(Suppl 4):S407-S411. PMID: 32038926.
      View in: PubMed
    5. Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May; 21(3):e191-e204. PMID: 31859066.
      View in: PubMed
    6. Pacheco JM. KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea? Transl Lung Cancer Res. 2019 Oct; 8(5):723-727. PMID: 31737510.
      View in: PubMed
    7. Pacheco JM, Byers LA. Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates? Cancer Discov. 2019 Oct; 9(10):1340-1342. PMID: 31575562.
      View in: PubMed
    8. Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW. Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs Today (Barc). 2019 Oct; 55(10):641-652. PMID: 31720561.
      View in: PubMed
    9. Pacheco JM, Gao D, Camidge DR. Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 =50%, but unanswered questions remain. Ann Transl Med. 2019 Jul; 7(Suppl 3):S127. PMID: 31576334.
      View in: PubMed
    10. Pacheco JM, Camidge DR, Doebele RC, Schenk E. A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer. Front Oncol. 2019; 9:195. PMID: 30984621.
      View in: PubMed
    11. Pacheco JM, Camidge DR. Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations. Lancet Respir Med. 2019 05; 7(5):366-367. PMID: 30922877.
      View in: PubMed
    12. Pacheco JM, Camidge DR. Is long-term survival possible for patients with stage IV ALK+ non-small cell lung cancer? Expert Rev Respir Med. 2019 05; 13(5):399-401. PMID: 30892100.
      View in: PubMed
    13. Pacheco J, Bunn PA. Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133. Clin Lung Cancer. 2019 05; 20(3):148-160.e2. PMID: 30686680.
      View in: PubMed
    14. Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, Robin T, Liu A, Karam S, Gaspar L, Kavanagh B, Rusthoven C, Aisner D, Doebele R, Camidge DR. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 04; 14(4):691-700. PMID: 30599201.
      View in: PubMed
    15. Patil T, Pacheco JM. Miliary Metastases in Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Nov 15; 379(20):1945. PMID: 30428292.
      View in: PubMed
    16. Pacheco JM, Camidge DR. Antibody drug conjugates in thoracic malignancies. Lung Cancer. 2018 10; 124:260-269. PMID: 30268471.
      View in: PubMed
    17. Robin TP, Camidge DR, Stuhr K, Nath SK, Breeze RE, Pacheco JM, Liu AK, Gaspar LE, Purcell WT, Doebele RC, Kavanagh BD, Rusthoven CG. Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 05; 13(5):715-720. PMID: 29269007.
      View in: PubMed
    18. Pacheco JM, Camidge DR. KEYNOTE-028: how do we use immunotherapy in small cell lung cancer? Transl Lung Cancer Res. 2017 Dec; 6(Suppl 1):S84-S87. PMID: 29299419.
      View in: PubMed
    19. Pacheco JM, Dimou A, Bunn PA. Advances in lung cancer. Oncotarget. 2017 Oct 03; 8(45):78247-78248. PMID: 29108218.
      View in: PubMed
    20. Tait S, Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Body mass index, diabetes, and triple-negative breast cancer prognosis. Breast Cancer Res Treat. 2014 Jul; 146(1):189-97. PMID: 24869799.
      View in: PubMed
    21. Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat. 2013 Feb; 138(1):281-9. PMID: 23400579.
      View in: PubMed
    Pacheco's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2020 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)